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ABSTRACT
Background: Autosomal recessive primary microcephaly
(MCPH) is a model disease to study human neurogenesis.
In affected individuals the brain grows at a reduced rate
during fetal life resulting in a small but structurally normal
brain and mental retardation. The condition is genetically
heterogeneous with mutations in ASPM being most
commonly reported.
Methods and results: We have examined this further by
studying three cohorts of microcephalic children to extend
both the phenotype and the mutation spectrum. Firstly, in
99 consecutively ascertained consanguineous families
with a strict diagnosis of MCPH, 41 (41%) were
homozygous at the MCPH5 locus and all but two families
had mutations. Thus, 39% of consanguineous MCPH
families had homozygous ASPM mutations. Secondly, in
27 non-consanguineous, predominantly Caucasian families
with a strict diagnosis of MCPH, 11 (40%) had ASPM
mutations. Thirdly, in 45 families with a less restricted
phenotype including microcephaly and mental retardation,
but regardless of other neurological features, only 3 (7%)
had an ASPM mutation. This report contains 27 novel
mutations and almost doubles the number of MCPH
associated ASPM mutations known to 57. All but one of
the mutations lead to the use of a premature termination
codon, 23 were nonsense mutations, 28 deletions or
insertions, 5 splicing, and 1 was a translocation.
Seventeen of the 57 mutations were recurrent. There
were no definitive missense mutations found nor was
there any mutation/phenotype correlation. ASPM muta-
tions were found in all ethnic groups studied.
Conclusion: This study confirms that mutations in ASPM
are the most common cause of MCPH, that ASPM
mutations are restricted to individuals with an MCPH
phenotype, and that ASPM testing in primary micro-
cephaly is clinically useful.
Our most defining feature as a species is our brain
with its large size and cognitive functions leading
to our great adaptability.
1 Many genes are involved
in the growth of the developing human brain but
the identification of those which have a non-
redundant and crucial role has proved difficult.
Autosomal recessive primary microcephaly
(MCPH) has emerged as a model disorder in which
to seek such genes, as it is a condition where fetal
brain growth is significantly reduced (as is head
size throughout life), brain architecture is normal,
and there are no apparent abnormalities in other
body systems.
2–4 Therefore the genes that cause
MCPH may be expected to have an important,
noticeable and non-redundant role in neurogenesis,
but not other developmental processes.
5 MCPH is
also a diagnosable cause of mental retardation, and
one with a substantial recurrence risk of one in
four in subsequent children.
The current diagnostic criteria for MCPH are:
congenital microcephaly more than 23 SD below
age and sex means; mental retardation but no
other neurological finding, such as spasticity,
seizures, or progressive cognitive decline; normal
height and weight, appearance, and results on
chromosome analysis and brain scan.
6 Despite this,
MCPH still remains a clinical diagnosis of exclu-
sion. Further, the recurrence risk of the MCPH
phenotype after one affected child (with careful
elimination of differential diagnoses) in a non-
consanguineous family is one in eight, and in a
consanguineous family one in six.
7–9 Our first aim
in designing this study was to be able to diagnose
MCPH with greater accuracy, particularly at an
early age, and to examine if the current diagnostic
criteria accurately reflect the phenotypic spectrum
of the disorder.
MCPH can be caused by recessive mutations in
up to seven genes.
46 Unexpectedly most of the
known MCPH genes, CDK5RAP2, ASPM and
CENPJ (better known as CPAP
10), encode centro-
somal proteins, highlighting the importance of the
centrosome in neurogenesis.
3 11–13 Despite this, a
common mechanism explaining the role of the
MCPH genes in neurogenesis has yet to emerge. All
four known MCPH proteins are also present in the
midbody (the microtubular structure linking
daughter cells at the final stage of cytokinesis)
and have apparently diverse roles: microcephalin in
DNA repair and chromosome condensation,
CDK5RAP2 and CENPJ in centriole/centrosome
replication, and ASPM in modulating the plane of
cytokinesis in neural precursors.
14–19 Mutations in
the ASPM gene at the MCPH5 locus on chromo-
some 1q31.3 have been considered the most
common cause of MCPH.
62 02 1Our second aim in
this study was to determine the frequency of
ASPM mutations in microcephalic individuals,
delineate the spectrum of mutations seen in the
ASPM gene, and evaluate the utility of sequencing
this gene in clinical practice.
The primary feature of MCPH is microcephaly—
a reduced occipitofrontal head circumference
(OFC)—which is an imperfect indicator of micro-
encephaly (a small brain). Ideally volumetric
magnetic resonance imaging (MRI) studies should
be performed to quantitate brain volume, but this
is not available in current clinical practice, whereas
head circumference charts are tried, tested and
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22–24 The choice of a cut-off value for microcephaly is
important but arbitrary. Half of mentally retarded individuals
are microcephalic
72 5and half of children with OFC of 22S Do r
less have normal intelligence.
26 To define microcephaly some
authors use an OFC ,2 SD below the mean for age and sex,
which results in 2% of the general population being considered
microcephalic.
27 28 Others use ,3 SD so that 0.1% of the general
population are microcephalic and most do have mental
retardation.
72 42 9Added to this are probable ethnic variations
and differences in norms between growth charts. Because of all
of these considerations we use an OFC of more than 23S Dt o
define microcephaly in this study, realising that it could exclude
a small number of true microcephalics but by corollary be
unlikely to include people with normal brain volumes or
intelligence.
METHODS
Three cohorts of microcephalic individuals were investigated.
The first cohort (cohort 1) is of 99 consecutively ascertained
consanguineous families of Pakistani or Arab origin seen by one
author (CGW), the first 56 of which have been previously partly
reported.
6 Seventy-three families had multiple affected members
and 26 consisted of a singleton child. No family was more
distantly related than parents being second cousins. All fulfilled
the current MCPH diagnostic criteria, with the exception that a
brain MRI scan was only available in eight families (all showed
no architectural anomalies). The second cohort (cohort 2) is of
27 non-consanguineous MCPH families of predominantly
European origin, including five sib pairs. All had a normal brain
scan and conformed to standard MCPH diagnostic criteria. The
third cohort (cohort 3) is of 45 children (from 45 families) that
was examined specifically to answer the questions, ‘‘Are the
current MCPH clinical criteria too restrictive?’’ and its corollary,
‘‘Do ASPM mutations cause a wider phenotype than just
MCPH?’’. All 45 children had congenital microcephaly and
mental retardation but there was no exclusion for the presence
of epileptic fits, spasticity or other gross motor problems,
growth problems, the presence of profound mental retardation
or brain malformations. All had a brain scan examined by one
author (WBD). The phenotypes of this cohort are given in
supplemental table 1. DNA was obtained from all affected
individuals and where possible their parents. Research ethics
approval was given for these studies by the host institutions.
We sought evidence of linkage to ASPM in all of the
consanguineous families. Polymorphic microsatellite marker or
SNP chip analysis of all affected members was performed using
standard methods and the results were examined for homo-
zygosity at the MCPH5 locus.
6 We sought a homozygous locus
size of .1 cM, based on our previous study of recessive
consanguineous families with proven recessive gene muta-
tions.
30 Of the total 99 consanguineous families, in 41 all
affected members were homozygous for the MCPH5 locus (33
multi-affected families and eight singletons). In the remaining
consanguineous families, affected family members were hetero-
zygous for the MCPH5 locus in the case of singletons, or
discordant for a MCPH5 haplotype in the multi-affected
families. These families were assumed unlinked and the
possibility of compound heterozygosity ignored.
31 No linkage
analysis was performed in the second two cohorts. The ASPM
gene was sequenced using genomic DNA of one affected
individual from each of the 41 consanguineous families that
were homozygous at the MCPH5 locus, and all of the cohort 2
and 3 families. All exons and splice sites were included. Our
recommended primers are given in supplemental table 2. All
mutations found were shown to segregate faithfully in the
family, although the degree of intrafamilial microcephaly varied,
as previously reported.
6
RESULTS
Of the consanguineous families in cohort 1, homozygous ASPM
mutations were found in 39/41 of families (95% of families that
were homozygous at the MCPH5 locus, 39% of all consangui-
neous families). Of the families that were homozygous at the
MCPH5 locus with no ASPM mutations, one had a singleton
affected child and one had an affected pair of first cousins. In
cohort 2, of non-consanguineous, predominantly Caucasian
individuals, ASPM mutations were found in 11/27 families
(40%), and in 3/5 sib pairs. In this cohort 19 mutations were
found: four were present in other cohorts, all but one led to a
premature termination codon and no novel missense mutations
were found. In three families the ASPM mutation was
homozygous and the remainder were compound heterozygotes.
In cohort 3, of 45 microcephalic individuals with a wider
phenotype we found mutations in three families (7%). One
consanguineous and one non-consanguineous singleton each
had a homozygous nonsense mutation. Both of these homo-
zygous mutations were present in other cohorts. A child from a
third family carried two heterozygous protein truncating
mutations. The mutations from all three cohorts and all
previously reported mutations are described in table 1 and
shown in fig 1.
DISCUSSION
This work brings the total number of different ASPM mutations
reported to 57. Of these mutations 17 are recurrent. All but one
of the mutations reported here and previously is predicted to
lead to the use of a premature termination codon in the ASPM
gene (which has no common splice variants) (table 1). Of the 57
mutations 23 were nonsense mutations, 28 were small deletions
or insertions leading to a change in the reading frame, and five
were splice site mutations again leading to the use of a
premature stop codon. In one family we found a large deletion
of 21 844 bases with the loss of exons 2 through to 13, but
which leaves the open reading frame intact. Cloning of the
deletion showed a loss of part of intron 1 through to intron 13,
and the breaks did not occur in repeat elements. A similar single
large deletion has been reported in the MCPH1 microcephalin
gene
32 and a translocation dissecting ASPM has previously been
reported.
33 The mutations were spread throughout the gene
with no hot-spots (fig 1). There were no clear cut genotype/
phenotype correlations of head size centile, degree of mental
retardation (profound mental retardation was not seen, nor has
it been reported in ASPM MCPH) or the presence of epileptic
fits with mutation type or position within the gene.
6 However,
only a few individuals in these cohorts have had an ethically
appropriate IQ test. The findings that the mutations were
spread throughout the ASPM gene, that all but one of the
mutations led to premature protein truncation, and that there
are no genotype/phenotype correlations, argue that the disease
mechanism causing MCPH is nonsense mediated decay of the
ASPM mRNA leading to a pronounced reduction of the protein
in neuroepithelial cells.
16 In support of this, two studies have
looked at non-neuroepithelial cells from ASPM MCPH patients
and found a combination of absent or much reduced levels of
ASPM protein and truncated versions of ASPM still containing
the C-terminus.
14 Presumably these truncated forms of
ASPM arise from atypical splicing events and/or translation
Original article
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Mutation Predicted protein effect
Reported in
more than one
family? Ethnic group Reference
c.74delG p.Arg25fs No Caucasian This paper
c.297+1460_3391-242del21844 Loss of microtubular binding domain No Caucasian This paper
c.349C.T p.Arg117X Yes Caucasian, Indian 20, 37
c.440delA p.Lys147fs No Caucasian This paper
c.577C.T p.Gln193X No Caucasian This paper
c.719_720delCT p.Ser240fs Yes Pakistani 3
c.1152_1153delAG p.Ser384fs No Caucasian This paper
c.1179delT p.Pro393fs No Caucasian This paper
c.1258_1264delTCTCAAG p.Ser420fs Yes Pakistani 3*
c.1260_1266delTCAAGTC p.Ser420fs Yes Pakistani 21*
c.1366G.T p.Glu456X No Turkish This paper
c.1406_1413delATCCTAAA p.Asn469fs No Caucasian This paper
c.1590delA p.Lys530fs No Caucasian This paper
c.1727_1728delAG p.Lys576fs No Yemeni 37
c.1959_1961delCAAA p.Asn653fs Yes Saudi Arabian, Caucasian This paper, 37
c.1990C.T p.Gln664X No Pakistani 37
c.2761-25A.G Creates ‘‘AG’’ motif between branch site and splice acceptor site,
exon 10 skipped, exon 11 frameshift with 30 novel aa then stop
No Caucasian This paper
c.2936+5G.T Removes splice donor site, additional 2 aa then stop No Pakistani 37
c.2967G.A p.Trp989X No Caucasian This paper
c.3055C.T p.Arg1019X Yes Caucasian This paper
c.3082G.A Removes splice donor site, additional 3 aa then stop No Pakistani 37
c.3188T.G p.Leu1063X No Pakistani This paper
c.3527C.G p.Ser1176X No Jordanian 37
c.3663delG p.Arg1221fs Yes Pakistani 37
c.3710C.G p.Ser1237X No Caucasian This paper
c.3741+1G.A Removes splice donor site, additional 9 novel aa then stop No Caucasian This paper
c.3796G.T p.Glu1266X No African This paper
c.3811C.T p.Arg1271X Yes Dutch{, Asian This paper, 37
c.3978G.A p.Trp1326X Yes Indian, Pakistani 20, 21
c.4581delA p.Gly1527fs No Pakistani 37
c.4795C.T p.Arg1599X No Pakistani 37
c.4855_4856delTA p.Tyr1619fs No Pakistani This paper
c.5136C.A p.Tyr1712X No Pakistani 37
c.5149delA p.Ile1717fs No Pakistani 34
c.6189T.G p.Tyr2063X No Yemeni 35
c.6335_6336delAT p.His2112fs No Pakistani This paper
c.7489_7493delTATAT p.Tyr2497fs No Caucasian This paper
c.7761T.G p.Tyr2587X Yes Pakistani This paper, 3
c.7782_7783delGA p.Gln2594fs Yes Caucasian, Pakistani This paper
c.7859_7860delAG p.Gln2620fs No Arab This paper
c.8130_8131delAA p.Thr2710fs No Caucasian This paper
c.8378delT p.Met2793fs Yes Pakistani This paper
c.8508_8509delGA p.Gln2836fs Yes Pakistani This paper, 34, 37
c.8844delC p.Ala2948fs No Caucasian This paper
c.9118_9119insCATT p.Tyr3040fs No Pakistani 21
c.9159delA p.Lys3053fs Yes Pakistani 3, 37
c.9178C.T p.Gln3060X Yes Indian, Caucasian This paper, 20
c.9190C.T p.Arg3064X Yes Pakistani, Dutch This paper, 37
c.9238A.T p.Leu3080X Yes Pakistani This paper, 21
c.9557C.G p.Ser3186X Yes Pakistani 21, 37
c.9681delA p.Thr3227fs No Pakistani This paper
c.9730C.T p.Arg3244X No Pakistani 34
c.9745_9746delCT p.Leu3249fs No Pakistani This paper
c.9754delA p.Arg3252fs No Yemeni 37
c.9789T.A p.Tyr3263X No Pakistani This paper
c.9984+1G.T Removes splice donor site, additional 29 novel aa then stop No Pakistani 37
c.10059C.A p.Tyr3353X No Pakistani 34
Translocation Loss of IQ and armadillo domains No European 33
aa, amino acids.
*These are the same 7 base pair deletion mutation. {c.3811C.T has been found in a total of 3 out of 5 Dutch families with MCPH.
Bold face indicates MCPH associated with epileptic fits.
The position of each mutation is given as the number of bases from the start codon of the reference sequence NM_018136.3.
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pithelial cells undergoing neurogenic mitosis, then this argues
that the MCPH phenotype only occurs when ASPM falls below
a critical level.
The role of missense mutations in ASPM remains obscure. We
found numerous sequence variants in study families whether
they had a premature protein truncating mutation or not
(supplemental table 3). Some of these were known single
nucleotide polymorphisms (SNPs), some we found recurrently
and some were unique to one family, but none would be
predicted to cause a loss of function. For the majority of families
we could show that parents were heterozygous for these
sequence variants, at least ruling out a dominant negative effect
(and the region is not known to be imprinted). An ASPM
missense mutation has been previously reported,
34 and while it
was the only mutation found in an MCPH5 linked family it
occurred in one of the 70+ IQ domains of the ASPM protein, and
its functional significance has not been investigated. So at
present there is no evidence that missense ASPM mutations
cause MCPH; however, it remains a possibility that missense
mutations may cause another phenotype or could cause
autosomal dominant microcephaly.
The first aim of this study was to re-examine the current
MCPH clinical criteria. We thought this necessary as the initial
MCPH criteria were defined in a research setting and we
wanted to see if these criteria were sufficiently robust to allow
early and accurate diagnosis. We achieved this by examining
which cases had ASPM mutations. Cohort 1 and 2 were
ascertained using the current criteria and in both a similar high
rate of ASPM mutations was found (39% and 40%, respec-
tively). This is particularly important as the two cohorts have
different ethnic and geographical origins as well as cohort 1
being inbred in contrast to cohort 2, which was not. So in these
two diverse groups the current criteria was an excellent
discriminator for ASPM mutations. If these data are taken with
previous segregation and clinical analyses which suggest that
three quarters of carefully selected cases of primary micro-
cephaly have MCPH, we can conclude that ASPM is the most
common cause of MCPH and accounts for one half of Asian and
European Caucasian MCPH cases. In contrast, when diagnostic
criteria were relaxed (as in cohort 3) to microcephalic children
with mental retardation, but not fulfilling the other MCPH
criteria, significantly fewer mutations were found (7%, p,0.01
Student t test, 2 df). Retrospective phenotype analysis showed
Figure 1 ASPM gene, protein and sites of autosomal recessive primary microcephaly (MCPH) mutations. (A) The exon/intron structure of the ASPM
gene. Exons are scaled relative to each other, with exon 18 being the largest at 4.7 kb. Introns vary significantly in size, but for clarity are all showna s
having the same arbitrary size. The position of the reported mutations is indicated, with italicised text denoting splicing mutations. All mutations are
detailed in table 1. (B) The known and predicted domains of the ASPM protein: a microtubule binding domain; two calponin homology (CH) domains
which are possibly responsible for transportation of the ASPM protein to the spindle poles; a region of 81 IQ/calmodulin binding domains; and a
conserved armadillo-like C-terminal domain of unknown significance. The regions of the ASPM protein affected by the previously reported translocation
breakpoint (Pichon et al
33) and the microdeletion first reported here are shown by an arrow and a bar, respectively.
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MCPH criteria (3/13). In those who did not meet the criteria
(n=32) no ASPM mutations were found.
We suggest one modification to add to the MCPH criteria,
that while epileptic fits are not common they should not be an
excluding factor. In cohort 1 there were tonic–clonic fits in some
affected individuals in two families with ASPM mutations; two
out of three affected in one family and both children in a second
family. The onset was after the first year of life, status
epilepticus did not occur, there was no regression associated
with the fits and they were easily controlled with standard
medications. A family with primary microcephaly and epileptic
fits and a protein truncating ASPM mutation has been
previously reported.
35 The ASPM mutations that have been
associated with epileptic fits are shown in table 1. A remaining
clinical problem is the necessity for mental retardation in the
diagnostic criteria of MCPH. This cannot always be reliably
diagnosed in the first few years of life, although a clinician may
be asked to comment on the diagnosis and prognosis of a
microcephalic baby or young child. Significant microcephaly
(OFC ,24 SD) alone can co-occur with normal intelligence in a
number of settings—for example, Bloom syndrome (OMIM
210900), osteodysplastic primordial dwarfism due to pericentrin
mutations (OMIM 210720), and autosomal dominant micro-
cephaly (OMIM 156580).
36 There are no reports of ASPM
mutations associated with microcephaly and normal intelli-
gence, and we found no examples of this in the families of this
study. Therefore, positive ASPM testing in a microcephalic baby
would be predictive of mental retardation.
The data in this study establish ASPM mutations as the most
common cause of MCPH, and that there are no genotype/
phenotype correlations. The data also indicate that ASPM
mutations are restricted to individuals with an MCPH
phenotype, and suggest ASPM testing in primary microcephaly
is clinically of use.
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